At Catamaran Bio, we are harnessing the power of our innovative TAILWIND™ Platform to develop safe and effective, off-the-shelf, allogeneic immune cell therapies to transform the treatment of cancer and immune disorders. Catamaran’s uniquely talented team is united by a commitment to always focus on “Patients First.” Catamaran was launched in 2020 and is backed by SV Health Investors.
- Vipin Suri Chief Scientific Officer
- Celeste Richardson SVP, Research
- Bharat Reddy Head of Business Development
- Mark Boshar Chief Operating Officer